Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Mounjaro Employer and ICHRA Coverage Navigation: How to Pay Less in 2026

By
Published Updated Last reviewed
5 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Mounjaro labeled uses / type 2 diabetes in adults and children 10 and older; CV risk reduction in adults with type 2 diabetes at high risk [1]
  • Employer-plan or ICHRA terms / not described in the Mounjaro label [1]
  • Original approval / NDA 215866, 2022-05-13 [2]
  • Dosing / start 2.5 mg once weekly; maximum 15 mg weekly in adults, 10 mg in children 10 and older [1]
  • Presentations / 2.5 mg to 15 mg; vial, prefilled single-dose pen, single-patient-use KwikPen [1][2]
  • Compounded tirzepatide / not FDA approved; shortage declared resolved 2024-12-19 [3][4]

Which Mounjaro prescriptions sit inside an approved use

Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. It is also approved to reduce the risk of major adverse cardiovascular events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes at high risk for those events [1]. Weight management and sleep apnea are indications of the sibling product Zepbound, not Mounjaro [1].

The Mounjaro label gives 2.5 mg once weekly as the starting dosage. It says that if additional glycemic control is needed, the dosage can be increased in 2.5 mg steps after at least 4 weeks on the current dose. The label's maximum is 15 mg weekly in adults and 10 mg weekly in pediatric patients 10 years and older [1]. The label names a vial, a prefilled single-dose pen and a single-patient-use KwikPen as presentations [1][2].

What the label does and does not cover

The Mounjaro label describes the approved uses, dosing and presentations. It does not describe employer-plan or ICHRA reimbursement terms [1]. Details such as formulary tier and prior-authorization criteria would have to come from the plan's own documents.

Where compounded tirzepatide stands

FDA declared the tirzepatide shortage resolved on 2024-12-19. The compounding transition periods ended for state-licensed pharmacies after the court denied the preliminary injunction on 2025-03-05, and for outsourcing facilities on 2025-03-19 [3].

Under FDA's described conditions, a compounded product must be made for an individual patient on a prescription. If it is essentially a copy of the approved drug, it generally must not be compounded regularly or in inordinate amounts, unless the prescriber documents a significant difference for an identified patient. FDA says it does not intend to take action against a compounder that fills four or fewer prescriptions of such a product in a calendar month [3]. FDA also says outsourcing facilities generally cannot compound from bulk substances unless the substance is on the outsourcing bulk list or the drug is on the shortage list, and that tirzepatide is on neither [3].

Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness or quality before they are marketed [4]. On 2026-04-30, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need. Public comment ran to 2026-06-29, and FDA said it would consider comments before making a final determination [5].

Frequently asked questions

Is Mounjaro FDA-approved for weight loss?
No. Mounjaro is approved for type 2 diabetes in adults and children 10 and older, and for cardiovascular risk reduction in adults with type 2 diabetes at high risk. Weight management is a Zepbound indication [1].
What is the maximum weekly Mounjaro dose?
The label gives a maximum of 15 mg once weekly in adults and 10 mg once weekly in children 10 and older. It lists a 2.5 mg starting dosage, with increases in 2.5 mg steps after at least 4 weeks on the current dose if more glycemic control is needed [1].
Does the Mounjaro label set what an employer plan or an ICHRA will pay?
No. The label describes approved uses, dosing and presentations. It does not describe employer-plan or ICHRA reimbursement terms [1].
Which Mounjaro presentations does the label name?
A vial, a prefilled single-dose pen and a single-patient-use KwikPen, in strengths from 2.5 mg to 15 mg [1][2].
Is compounded tirzepatide still allowed?
Only under conditions. FDA declared the shortage resolved on 2024-12-19, and the transition periods ended in early 2025. A compounded product must be made for an individual patient on a prescription. If it is essentially a copy of the approved drug, it generally must not be made regularly or in inordinate amounts, unless the prescriber documents a significant difference for an identified patient [3].
Does compounded tirzepatide get FDA review?
No. Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [4].

References

  1. U.S. National Library of Medicine, DailyMed. Mounjaro injection and KwikPen (tirzepatide) prescribing information. Mounjaro injection and KwikPen (tirzepatide) label
  2. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  3. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
  4. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
  5. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on Bulks List | FDA
Evidence overview for Mounjaro Employer and ICHRA Coverage Navigation: How to Pay Less in 2026